The Cooper Cos. (NYSE:COO) – Investment analysts at Northcoast Research lowered their Q1 2017 EPS estimates for The Cooper Cos. in a research note issued on Monday. Northcoast Research analyst D. Keiser now expects that the firm will post earnings of $2.11 per share for the quarter, down from their previous forecast of $2.12.

The Cooper Cos. (NYSE:COO) last announced its quarterly earnings results on Thursday, September 1st. The medical device company reported $2.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.29 by $0.01. The business had revenue of $514.70 million for the quarter. The Cooper Cos. had a net margin of 13.14% and a return on equity of 14.89%. The Cooper Cos.’s revenue was up 11.5% on a year-over-year basis. During the same period last year, the business earned $1.97 EPS.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/12/01/northcoast-research-brokers-cut-earnings-estimates-for-the-cooper-cos-coo.html.

Earnings History and Estimates for The Cooper Cos. (NYSE:COO)

A number of other equities analysts have also issued reports on the stock. Wells Fargo & Co. reissued a “hold” rating on shares of The Cooper Cos. in a research report on Sunday, September 11th. Jefferies Group raised their price target on shares of The Cooper Cos. from $190.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, August 24th. Robert W. Baird raised their price target on shares of The Cooper Cos. from $185.00 to $196.00 and gave the stock an “outperform” rating in a research report on Thursday, August 18th. Stifel Nicolaus raised their price target on shares of The Cooper Cos. from $195.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, August 31st. Finally, Zacks Investment Research lowered shares of The Cooper Cos. from a “buy” rating to a “hold” rating in a report on Monday, October 31st. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $187.80.

Shares of The Cooper Cos. (NYSE:COO) opened at 164.49 on Tuesday. The company has a market cap of $8.02 billion, a price-to-earnings ratio of 32.21 and a beta of 0.62. The Cooper Cos. has a one year low of $119.28 and a one year high of $190.99. The firm has a 50-day moving average of $175.49 and a 200-day moving average of $175.95.

A number of large investors have recently made changes to their positions in the company. Ameriprise Financial Inc. boosted its stake in shares of The Cooper Cos. by 18.4% in the third quarter. Ameriprise Financial Inc. now owns 1,604,879 shares of the medical device company’s stock valued at $287,683,000 after buying an additional 249,844 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of The Cooper Cos. by 477.2% in the second quarter. Point72 Asset Management L.P. now owns 268,400 shares of the medical device company’s stock valued at $46,049,000 after buying an additional 221,900 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of The Cooper Cos. during the third quarter valued at about $36,963,000. Eaton Vance Management boosted its stake in shares of The Cooper Cos. by 2,370.6% in the second quarter. Eaton Vance Management now owns 213,214 shares of the medical device company’s stock valued at $36,581,000 after buying an additional 204,584 shares during the period. Finally, Pioneer Investment Management Inc. acquired a new stake in shares of The Cooper Cos. during the third quarter valued at about $33,715,000. 98.06% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/12/01/northcoast-research-brokers-cut-earnings-estimates-for-the-cooper-cos-coo.html.

In other The Cooper Cos. news, Director William A. Kozy bought 270 shares of the stock in a transaction on Tuesday, September 6th. The shares were bought at an average price of $186.69 per share, with a total value of $50,406.30. Following the purchase, the director now directly owns 770 shares in the company, valued at approximately $143,751.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Albert G. White III sold 20,000 shares of The Cooper Cos. stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $185.72, for a total transaction of $3,714,400.00. Following the sale, the executive vice president now directly owns 41,639 shares in the company, valued at approximately $7,733,195.08. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.

About The Cooper Cos.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

5 Day Chart for NYSE:COO

Receive News & Stock Ratings for The Cooper Cos. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Cos. and related stocks with our FREE daily email newsletter.